---
title: "Weekly Recap | Editas Medicine -16.41%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298801439.md"
description: "Editas Medicine (EDIT) fell 16.41% this week to close at $2.70, while the S&P 500 slipped 0.8%, leaving the stock about 15.61 percentage points behind. The four-session week tracked a sustained slide: Tuesday opened at $3.20, hit a high of $3.215, then faded to $3.03; Wednesday dropped to $2.77; Thursday touched the weekly low of $2.62 before closing at $2.65; Friday edged back to $2.70. Intraweek amplitude was 18.59% on heavier turnover, with average daily volume around 2."
datetime: "2026-09-12T08:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298801439.md)
  - [en](https://longbridge.com/en/news/298801439.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298801439.md)
generator: "portal-rs"
---

# Weekly Recap | Editas Medicine -16.41%, consensus target above spot

## The Week

Editas Medicine (EDIT) fell 16.41% this week to close at $2.70, while the S&P 500 slipped 0.8%, leaving the stock about 15.61 percentage points behind. The four-session week tracked a sustained slide: Tuesday opened at $3.20, hit a high of $3.215, then faded to $3.03; Wednesday dropped to $2.77; Thursday touched the weekly low of $2.62 before closing at $2.65; Friday edged back to $2.70. Intraweek amplitude was 18.59% on heavier turnover, with average daily volume around 2.56m shares, up roughly 24% from the median. The close sits below both the 20-day moving average of $3.02 and the 60-day average of $2.97.

## Key Events

The week’s company news centred on a leadership change. On 8 September Editas appointed Dan Ory as chief medical officer; the next day the company granted Ory 950,000 stock options at an exercise price of $3.03 each, followed by an initial beneficial ownership filing on 10 September. In parallel, Editas disclosed progress on EDIT-401: on 9 September reports said the company plans a first-in-human trial for the CRISPR cholesterol therapy, and on 12 September it said it is targeting 2026 patient dosing for the LDL gene-editing programme. On the filing side, the week’s substantive item was an S-8 form, consistent with the option grant.

## Analyst Ratings

Thirteen brokers cover the stock: 7 rate it strong buy, 4 hold, and 2 underweight, with a consensus rating of buy. The consensus target price is $6, about 122.22% above the last close of $2.70. Target estimates are wide apart, from $1 to $15, pointing to divergent views on EDIT-401. Within biotechnology, Editas ranks 79th out of 506 names on analyst rating strength.

## The Week Ahead

Macro data dominates the next session. The New York Fed manufacturing index lands on 15 September, with a prior reading of 20.6 and a forecast of 14.75. On 16 September retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA crude inventories are all due. For Editas, the key question is whether the company adds execution detail to its 2026 patient-dosing target for LDL gene editing now that the first-in-human trial plan for EDIT-401 is out.

## In Short

Editas moved on both management and pipeline this week, and the broker consensus remains constructive, yet the stock fell more than 16% and closed below its moving averages. That gap between analyst targets and market pricing is the tension to watch. The next test is whether the EDIT-401 first-in-human trial and the LDL gene-editing timeline firm up into concrete milestones.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [EDIT.US](https://longbridge.com/en/quote/EDIT.US.md)

## Related News & Research

- [Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy](https://longbridge.com/en/news/298778598.md)
- [Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401](https://longbridge.com/en/news/298444880.md)
- [Editas Medicine Q2 net loss narrows and beats estimates](https://longbridge.com/en/news/295007397.md)
- [Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement](https://longbridge.com/en/news/295279253.md)
- [EDIT: Director elections, compensation, and auditor ratification passed; EDIT-401 clinical plans advanced](https://longbridge.com/en/news/290061206.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**